RxDoctor Payments Data

Shital Pema, DPM

Primary Podiatric Medicine · Kettering, OHNPI 1780640995

Payments from drug & device makers

What this record shows

This record is dominated by other: $237,254 of the $298,665 with a category attached, or 79.4%. Johnson & Johnson accounts for 79.5% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $237,642 and has fallen 98.4% since, to $3,903 in 2025.

$298,665in general payments, 2019–2025

Across 213 payments — averaging $1402.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$237K
  • Bone Support Inc.$15K
  • DNE LLC$12K
  • Orthofix Medical, Inc.$5K
  • CDC Medical LLC$5K
  • Stryker$4K
  • plus $20K from 26 others

What the payments were for

  • Consulting fees$21,8757%
  • Speaking & faculty fees$10,0003%
  • Travel & lodging$23,0328%
  • Food & beverage$4,8652%
  • Education$1,6401%
  • Other$237,25479%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few primary podiatric medicine providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$154,140
Medicare patients
397
Services billed
1,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.19$6,156
Enoxaparin Sodium13$835
Celecoxib16$568
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen49$291
Ammonium Lactate17$241
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav37$214
Cephalexin26$153
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim25$93
Doxycycline Hyclate12$91
Methylprednisolone11$84
Ibuprofen29$76
Tramadol Hcl17$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$2,116$6,15619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few primary podiatric medicine providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other primary podiatric medicine in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →